Teva Pharmaceutical Industries (TEVJF) Return on Capital Employed (2018 - 2026)

Teva Pharmaceutical Industries has disclosed Return on Capital Employed across 9 years of filings, most recently posting 8.52% for Q1 2026.

• Quarterly Return on Capital Employed rose 696.0% year-over-year to 8.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.52% (up 696.0% YoY) and the FY2025 annual result came in at 8.11%, up 917.0% from the prior year.
• Return on Capital Employed advanced to 8.52% in Q1 2026, from 8.03% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 8.52% in Q1 2026 and troughed at 6.72% in Q4 2022.
• A 5-year average of 0.59% and a median of 1.42% in 2023 frame the typical range for Return on Capital Employed.
• Biggest YoY gain for Return on Capital Employed was 1042 bps in 2022; the steepest drop was 1140 bps in 2022.
• Tracing TEVJF's Return on Capital Employed over 5 years: stood at 6.72% in 2022, then jumped by 121 bps to 1.42% in 2023, then slumped by 177 bps to 1.09% in 2024, then surged by 835 bps to 8.03% in 2025, then increased by 6 bps to 8.52% in 2026.
• Business Quant data shows TEVJF's Return on Capital Employed at 8.52% in Q1 2026, 8.03% in Q4 2025, and 6.41% in Q3 2025.